Rapid Micro Biosystems (RPID) to Release Quarterly Earnings on Friday

Rapid Micro Biosystems (NASDAQ:RPID) is expected to be announcing its Q1 2026 results before the market opens on Friday, May 8th. Analysts expect the company to announce earnings of ($0.25) per share and revenue of $7.60 million for the quarter. Investors are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Friday, May 15, 2026 at 8:30 AM ET.

Rapid Micro Biosystems (NASDAQ:RPID) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.05). Rapid Micro Biosystems had a negative net margin of 140.30% and a negative return on equity of 95.40%. The company had revenue of $11.28 million for the quarter, compared to analysts’ expectations of $10.93 million. On average, analysts expect Rapid Micro Biosystems to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Rapid Micro Biosystems Stock Performance

NASDAQ:RPID opened at $2.48 on Wednesday. The stock’s fifty day moving average is $2.86 and its 200 day moving average is $3.36. Rapid Micro Biosystems has a fifty-two week low of $2.01 and a fifty-two week high of $4.94. The firm has a market capitalization of $112.74 million, a PE ratio of -2.32 and a beta of 1.52. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.36 and a current ratio of 3.31.

Insider Buying and Selling at Rapid Micro Biosystems

In other Rapid Micro Biosystems news, COO John J. Addington Wilson sold 9,603 shares of the company’s stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $4.32, for a total value of $41,484.96. Following the transaction, the chief operating officer owned 316,762 shares of the company’s stock, valued at $1,368,411.84. This represents a 2.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Sean M. Wirtjes sold 17,254 shares of the company’s stock in a transaction on Friday, February 20th. The shares were sold at an average price of $3.92, for a total value of $67,635.68. Following the completion of the transaction, the chief financial officer directly owned 563,674 shares in the company, valued at $2,209,602.08. This trade represents a 2.97% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 119,466 shares of company stock valued at $474,109 in the last quarter. 12.70% of the stock is owned by insiders.

Hedge Funds Weigh In On Rapid Micro Biosystems

Hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC grew its position in Rapid Micro Biosystems by 1.6% in the 2nd quarter. Geode Capital Management LLC now owns 204,079 shares of the company’s stock valued at $704,000 after acquiring an additional 3,143 shares during the last quarter. Vanguard Group Inc. grew its position in Rapid Micro Biosystems by 6.7% in the 3rd quarter. Vanguard Group Inc. now owns 965,018 shares of the company’s stock valued at $3,223,000 after acquiring an additional 60,655 shares during the last quarter. 683 Capital Management LLC bought a new position in Rapid Micro Biosystems in the 4th quarter valued at $350,000. Renaissance Technologies LLC grew its position in shares of Rapid Micro Biosystems by 4.9% during the 4th quarter. Renaissance Technologies LLC now owns 115,627 shares of the company’s stock worth $335,000 after buying an additional 5,440 shares in the last quarter. Finally, Jane Street Group LLC grew its position in shares of Rapid Micro Biosystems by 176.1% during the 4th quarter. Jane Street Group LLC now owns 105,301 shares of the company’s stock worth $305,000 after buying an additional 67,161 shares in the last quarter. Institutional investors own 52.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on RPID shares. Wall Street Zen upgraded Rapid Micro Biosystems from a “sell” rating to a “hold” rating in a report on Sunday, April 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Rapid Micro Biosystems in a report on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $8.00.

About Rapid Micro Biosystems

Rapid Micro Biosystems (NASDAQ: RPID) develops and commercializes automated microbial detection and contamination control solutions for the life sciences industry. Its flagship offering, the Growth Direct® System, leverages digital imaging and proprietary growth indicator plates to identify and count microorganisms more rapidly than traditional culture-based methods. The company’s technology platform is designed to streamline quality control workflows in pharmaceutical, biotechnology and vaccine manufacturing settings, helping clients reduce release times and improve operational efficiency.

In addition to the Growth Direct® System, Rapid Micro Biosystems offers an integrated suite of software and consumables that support automated data capture, analysis and reporting.